C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s.
Henry
Keith
K
HIV Program Hennepin County Medical Center, University of Minnesota, Minneapolis, MN, USA.
Kitch
Douglas
D
Dube
Michael
M
Zackin
Robert
R
Parker
Robert A
RA
Sprecher
Dennis
D
Hammer
Scott
S
Currier
Judith
J
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002097:C-Reactive Protein / Q000378:metabolism*; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000139:chemically induced*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000009:adverse effects*; D008297:Male; D012307:Risk Factors
D017320:HIV Protease Inhibitors; D019469:Indinavir; D002097:C-Reactive Protein